- Works count
- 212
- Citation count
- 18,511
- H-index
- 34
- i10-index
- 62
Research interests
Publications
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.00174
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.00149
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31257-1
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1606774
Current projects
No projects listed.